Aethlon Medical, Inc. (AEMD)
NASDAQ: AEMD · Real-Time Price · USD
2.120
+0.160 (8.16%)
Feb 17, 2026, 4:00 PM EST - Market closed
Company Description
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States.
It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation.
The company was founded in 1984 and is based in San Diego, California.
Aethlon Medical, Inc.
| Country | United States |
| Founded | 1984 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 9 |
| CEO | James Frakes |
Contact Details
Address: 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 United States | |
| Phone | 619 941 0360 |
| Website | aethlonmedical.com |
Stock Details
| Ticker Symbol | AEMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0000882291 |
| CUSIP Number | 00808Y604 |
| ISIN Number | US00808Y6041 |
| Employer ID | 13-3632859 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James B. Frakes M.B.A. | Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Secretary and Director |
| Dr. Steven P. LaRosa M.D. | Chief Medical Officer |
| Michele Bombardiere | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 12, 2026 | 10-Q | Quarterly Report |
| Feb 12, 2026 | 8-K | Current Report |
| Jan 27, 2026 | 424B3 | Prospectus |
| Jan 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 26, 2026 | 8-K | Current Report |
| Jan 16, 2026 | EFFECT | Notice of Effectiveness |
| Jan 16, 2026 | 424B3 | Prospectus |
| Jan 16, 2026 | DEF 14A | Other definitive proxy statements |